These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 19692114

  • 1. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA.
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [Abstract] [Full Text] [Related]

  • 2. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC, Crain EJ, Watson CA, Hua J, Schumacher WA, Rehfuss R.
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA, Jeske WP, Fareed J.
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M.
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [Abstract] [Full Text] [Related]

  • 9. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC, Crain EJ, Watson CA, Jiang X, Hua J, Bostwick JS, Ogletree ML, Schumacher WA, Rehfuss R.
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
    Dobesh PP.
    Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ADP receptors: inhibitory strategies for antiplatelet therapy.
    Cattaneo M.
    Drug News Perspect; 2006 Jun; 19(5):253-9. PubMed ID: 16941047
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
    Niitsu Y, Jakubowski JA, Sugidachi A, Asai F.
    Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA, Winters KJ, Naganuma H, Wallentin L.
    Cardiovasc Drug Rev; 2007 Apr; 25(4):357-74. PubMed ID: 18078435
    [Abstract] [Full Text] [Related]

  • 19. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
    Tomizawa A, Ohno K, Jakubowski JA, Mizuno M, Sugidachi A.
    Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
    Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A.
    Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.